Latest filingSep 08, 2026Most recent Form 4
DYN
Dyne Therapeutics, Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/09 to 09/09. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$6.56B15 sells
Net open-market-$6.56B5 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period15transactions
- S · Open-market sells · dominant15 · 100%
Activity by reported role
A joint filing can contribute to multiple roles17transactions
- Director · dominant6 · 35%
- CCO3 · 18%
- CMO3 · 18%
- Chief executive officer2 · 12%
- PRES2 · 12%
- Chief financial officer1 · 6%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (5)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeRhodes Jason PCommon Stock · Indirect · See footnote
2,441,454Aug 14, 2026
Kerr DouglasCommon Stock · Direct
162,564Sep 08, 2026
Friedl-Naderer JohannaCommon Stock · Direct
152,897Sep 08, 2026
Cox JohnCommon Stock · Direct
357,507Sep 08, 2026
Lucera ErickCommon Stock · Direct
119,766Aug 13, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 09 → Sep 09
LessMore
Top insiders
By absolute net value across the selected period- RP-$65.2M
- CJ-$237.9k
- KD-$156.4k
- LE-$47.2k
- FJ-$31.3k
Recent filing activity
Most recent 12 transactions · color = transaction codeFiling detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
DYN transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| DYN | Friedl-Naderer Johanna | CCO | sale10b5-1 | 185 | -$349k | S | — | 0.0% | 09/08 | 09/08 |
| DYN | Friedl-Naderer Johanna | CCO | sale10b5-1 | 900 | -$2.19M | S | — | 0.0% | 09/08 | 09/04 |
| DYN | Kerr Douglas | CMO | sale10b5-1 | 1.29k | -$2.43M | S | — | 0.0% | 09/08 | 09/08 |
| DYN | Kerr Douglas | CMO | sale10b5-1 | 3.74k | -$9.11M | S | — | 0.0% | 09/08 | 09/04 |
| DYN | Cox John | CEOPRES | sale10b5-1 | 5.65k | -$10.6M | S | — | 0.0% | 09/08 | 09/08 |
| DYN | Rhodes Jason P | DIR | sale10b5-1 | 322k | -$806M | S | −4.0% | 08/17 | 08/14 | |
| DYN | Rhodes Jason P | DIR | sale10b5-1 | 478k | -$1.19B | S | −4.0% | 08/17 | 08/14 | |
| DYN | Rhodes Jason P | DIR | sale10b5-1 | 1.35M | -$3.39B | S | −4.0% | 08/17 | 08/14 | |
| DYN | Rhodes Jason P | DIR | sale10b5-1 | 63.6k | -$166M | S | −4.0% | 08/17 | 08/13 | |
| DYN | Rhodes Jason P | DIR | sale10b5-1 | 94.4k | -$247M | S | −4.0% | 08/17 | 08/13 | |
| DYN | Rhodes Jason P | DIR | sale10b5-1 | 268k | -$703M | S | −4.0% | 08/17 | 08/13 | |
| DYN | Friedl-Naderer Johanna | CCO | sale10b5-1 | 226 | -$593k | S | −4.0% | 08/17 | 08/13 | |
| DYN | Kerr Douglas | CMO | sale10b5-1 | 1.55k | -$4.08M | S | −4.0% | 08/17 | 08/13 | |
| DYN | Cox John | CEOPRES | sale10b5-1 | 4.98k | -$13.1M | S | −4.0% | 08/17 | 08/13 | |
| DYN | Lucera Erick | CFO | sale10b5-1 | 1.79k | -$4.72M | S | −4.0% | 08/17 | 08/13 |
Dyne Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Dyne Therapeutics, Inc.?
Friedl-Naderer Johanna, Kerr Douglas, Cox John, Rhodes Jason P, Lucera Erick.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Friedl-Naderer Johanna reported a sale on Sep 08, 2026 valued at $349k. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $65,657,759.39. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.